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BACKGROUND: Angiogenesis is fundamental to the progression of many solid tumours including prostate cancer. Sodium selenate is a
small, water-soluble, orally bioavailable activator of PP2A phosphatase with anti-angiogenic properties.
METHODS: This was a dose-escalation phase I study in men with asymptomatic, chemotherapy-naı ¨ve, castration-resistant prostate
cancer. The primary objective was to determine the maximum tolerated dose (MTD). Secondary objectives included establishing the
safety, tolerability and pharmacokinetic profile.
RESULTS: A total of 19 patients were enrolled. The MTD was 60mg per day. Dose-limiting toxicity (fatigue and diarrhoea) was
observed at 90mg per day. The most frequently reported treatment-related adverse events across all treatment cohorts were
nausea, diarrhoea, fatigue, muscle spasms, alopecia and nail disorders. No grade 4 toxicities were observed and there were no deaths
on study. Linear pharmacokinetics was observed. One patient had a PSA response 450%. Median time to PSA progression (for non-
responders) was 14.2 weeks. Mean PSA doubling time increased during the main treatment phase from 2.18 months before trial to
3.85 months.
CONCLUSION: Sodium selenate is well tolerated at a dose of 60mg per day with modest single-agent efficacy similar to other
anti-angiogenic agents. Further trials in combination with conventional cytotoxic regimens are warranted.
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Prostate carcinoma is a common cancer, which is lethal in up to
15% of patients (Baade et al, 2004; Jemal et al, 2009). The vast
majority of patients die from castrate-resistant disease, evidenced
by continued tumour progression despite low levels of circulating
androgens. The ability of traditional cytotoxic agents to affect
meaningfully on survival is limited, with the most efficacious
docetaxel-based regimens extending median survival by just more
than 2 months. There is thus an urgent need for new agents that
either significantly affect the disease as a stand-alone agent or
sensitise tumours to existing therapies.
The ability to independently initiate new blood vessel formation
is a ‘hallmark’ of solid tumours. The importance of angiogenesis in
the development and progression of prostate cancer is under-
scored by numerous studies evaluating microvessel density
(MVD), a histological correlate of angiogenic potential, in human
prostate samples. The MVD of prostate cancer is consistently
higher than normal tissue, and is positively associated with more
advanced tumour stage, higher Gleason scores, and the presence of
metastatic disease. In addition, MVD predicts biochemical
recurrence after both radical prostatectomy and external beam
radiotherapy (Halvorsen et al, 2000; Revelos et al, 2007), and when
used with other markers of angiogenic potential, predicts overall
survival (Mucci et al, 2009). Similarly, significantly higher levels of
VEGF, the predominant pro-angiogenic signalling molecule, are
detected in patients with metastatic disease, and in hormone
refractory prostate cancer, when both serum and urine levels
predict survival (Bok et al, 2001; George et al, 2001). Over the last
two decades the role of protein kinases in co-ordinating cancer-
related neo-angiogenesis through the ‘switch-like’ reversible
phosphorylation of key regulatory molecules in response to pro-
angiogenic signals has been extensively elaborated (Ahmed and
Bicknell, 2009; Aragon-Ching and Dahut, 2009). On the basis of
this knowledge a number of antibodies and small-molecule kinase
inhibitors that target pro-angiogenic signalling have been devel-
oped, and have been successfully translated to clinical use in renal,
breast, non-small cell lung, colorectal and hepatic carcinoma
(Ivy et al, 2009). At the same time, relatively little attention has been
paid to the role of protein phosphatases, molecules that promote
subsequent dephosphorylation, in limiting or even suppressing
pro-angiogenic signalling. We have identified a specific selenium-
containing compound, sodium selenate, which significantly boosts
the activity of a key intracellular phosphatase, PP2A (Corcoran
et al, 2010). PP2A has been shown to negatively regulate a number of
intracellular proteins that are important in angiogenic signalling,
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sparticularly components of the PI3K/Akt and MAPK pathways, in
endothelial cells (Young et al, 2002; Young, 2004; Kim et al, 2009).
We have previously shown that sodium selenate inhibits experi-
mental tumour growth in an orthotopic model of castration-
resistant prostate cancer (CRPC) by inhibiting vessel branching
(Corcoran et al, 2004). This first-time-in-human study examined
the novel PP2A stimulator, sodium selenate, in men with CRPC.
The primary aims of this study were to assess the safety,
tolerability and pharmacokinetics of sodium selenate in men with
CRPC.
PATIENTS AND METHODS
Patient selection
Patients with CRPC defined by at least three successive rises in
serum PSA at least 2 weeks apart, in the presence of castrate levels
of serum testosterone, were eligible for enrolment in this study.
Anti-androgen therapy must have been discontinued at least
4 weeks before entry into the trial, with evidence of continuing PSA
rises after this time, with a PSA level X5mgl
–1 required at study
entry. LHRH agonists were continued and allowed concurrently. In
addition, patients were required to be asymptomatic or have only
minor symptoms due to their prostate cancer, have a WHO
performance status p2, and an estimated life expectancy of at least
6 months. Patients were also required to have adequate renal
(serum creatinine o1.5 ULRR), liver (serum bilirubin o1.25 and
AST/ALT o2.5 ULRR) and haematological reserve (absolute
neutrophil count 41 10
9l
–1 and platelets 4100 10
9l
–1), and
have no evidence of severe or uncontrolled systemic disease.
Patients treated previously with cytotoxic chemotherapy or
strontium therapy, or who had coexisting malignancies or
malignancies diagnosed within the last 5 years (with the exception
of non-melanomatous skin cancer), were ineligible for enrolment.
Treatment with any investigational agent within 4 weeks of study
entry was not allowed, and patients with unresolved chronic
toxicity greater than Common Terminology Criteria grade 2 from
previous anti-cancer therapy or incomplete healing from previous
surgery were excluded. Although the previous use of commercially
available selenium supplementation was not a specific exclusion
criterion, concomitant use over the study period was not
permitted. Similarly, the concomitant use of unapproved or herbal
remedies for prostate cancer was prohibited during the study
period.
The study received institutional review board approval and all
patients gave written informed consent.
Study design and treatment plan
This was an open-label phase I dose-escalation study. After signing
informed consent, patients underwent baseline testing to confirm
eligibility. Patients who satisfied the inclusion and exclusion
requirements were invited to enter the study according to the dose-
escalation criteria. Baseline evaluations were conducted within
2 weeks of starting therapy. Sodium selenate was administered
daily for 3 weeks (one cycle). After four cycles of therapy
(12 weeks), patients with stable or responding disease, and who
wished to continue on study, were offered ongoing treatment for a
further 12 weeks. During the main treatment phase (weeks 0–12)
patients underwent assessments for safety and tolerability at the
end of each cycle. Patients opting to continue the drug beyond this
time were similarly evaluated at six weekly intervals. All patients
were assessed for safety 28 days after the last dose of study drug,
and where possible, all patients were evaluated 3 months after their
final treatment with sodium selenate.
At study commencement, sodium selenate was administered as
an oral capsule taken once a day on an outpatient basis. Patients
were given a fixed dose and there was no intra-patient dose-
escalation. After the initial pharmacokinetic analysis demonstrated
a short drug half-life in serum, the same total daily dose was given
in three divided doses in one 24-h period to generate steady-state
plasma selenate levels (beginning with patient 5).
For the initial dose levels, an accelerated titration design was
used with one patient at each dose (5mg, 10mg, 15mg, 30mg)
treated and evaluated at the end of 3 weeks. Toxicities were graded
according to Common Terminology Criteria for Adverse Events
version 3. Drug-related toxicity (DRT) was defined as any grade 2
non-haematological toxicity and/or any grade 3 haematological
toxicity. In the absence of a DRT, commencement of a patient at
the next dose level occurred. Three patients were subsequently
enrolled to each fixed-dose cohort, with planned dose levels of 60,
90 and 120mg per day. The protocol was later amended to include
45mg per day to collect additional safety information. Dose-
escalation continued until dose-limiting toxicity (DLT) was
observed in one-third of patients during cycle 1. The DLT was
defined as any grade 3/4 non-haematological toxicity and/or and
grade 4 haematological toxicity. If DLT was observed in one of
three patients in a cohort, a further three patients were recruited to
that dose level. If one further patient experienced DLT, then this
defined the DLT level. If no DLT was observed, patients were
recruited to the next dose level. The maximum tolerated dose
(MTD) was defined as the dose level below that in which X33%
(2 of 6) of patients were observed to have a DLT. The MTD was
then expanded to six patients.
If patients developed X grade 2 haematological and/or non-
haematological toxicity during the main treatment phase, sodium
selenate was not administered. If treatment was deferred because
of toxicity, it could be re-initiated once toxicity was p grade 1.
Treatment delays of up to 2 weeks were allowed, but no dose
reductions were permitted. In the absence of treatment delays due
to adverse events, treatment continued for up to four cycles or
until the disease progressed, the occurrence of an inter-current
illness that prevented further administration of treatment, or the
patient decided to withdraw from the study. In the absence of
toxicity, patients were allowed to remain on selenate beyond the
main treatment phase if they chose to do so.
Drug product
Sodium selenate was blended with the inert pharmaceutical
excipient lactose and filled into capsules using a Dott Bonapace
(Milan, Italy) semi-automatic capsule filler, under GMP condi-
tions, using the appropriate size capsules. Three dosage strengths
were prepared, containing 5, 20 or 50mg of sodium selenate.
Independent quality control testing was performed on the finished
product, and stability at 251C for the time course of the study
confirmed.
Patient evaluation
Before registration, a complete medical history and physical
examination were performed, castrate levels of serum testosterone
confirmed, and baseline haematology and biochemistry were
obtained. Patients were then evaluated at the start of each
treatment cycle for possible adverse events or toxicity (perfor-
mance status, physical examination, electrocardiogram, full blood
count, urea and electrolytes, liver function tests). All patients
entering the trial had an additional safety visit at 4 and 12 weeks
after completion of therapy to assess for residual toxicity. To
assess for tumour response, serum PSA was measured at the
completion of each treatment cycle. Although the trial was initiated
before the publication of the Prostate Cancer Trials Working
Group 2 criteria for PSA end points, PSA data are analysed
according to their recommendations (Scher et al, 2008). In
particular, the percentage change in PSA from baseline to the
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scompletion of initial 12-week evaluation, or date of withdrawal
from study if earlier, is presented in a waterfall plot. For patients
experiencing an initial decline in PSA, time to PSA progression is
defined by the date of documentation of PSA X25% above
nadir with an absolute increase of X2ngml
–1 confirmed on a
second reading X3 weeks later. For patients not experiencing a
decline in baseline PSA, the date of progression is defined by the
date of documentation of PSA X25% with an absolute increase
X2ngml
–1 above baseline, after 12 weeks on treatment. In
addition, PSA doubling time was calculated using the log-slope
method as previously described (Daskivich et al, 2006). For pre-
trial PSA measurements, a weighted linear regression was
performed, with PSA measurements 416 weeks before study
entry discounted by 50%. All other PSA values, including those on
trial, were given equal weighting (weight¼1). To calculate the
mean cohort doubling time, the slopes of individual regression
equations were averaged and its inverse multiplied by the log of 2.
Pharmacokinetic studies
Blood samples were obtained from all patients during their first
course of treatment, at the following time points: pre-dose (within
60min of drug administration), post-dose at 30min, 1, 2, 4, 6, 24,
48 and 72h. In addition, trough samples were taken at days 7, 14
and 21. Samples of 10ml were collected into potassium–EDTA
tubes from an indwelling arm vein catheter, and centrifuged at
2000g at 41C for 15min. The plasma was immediately stored at
 801C. Urine was collected over a 24-h period immediately after
the first dose on day 1. The 24-h urine sample was thoroughly
mixed, volume recorded and a 6-ml aliquot was taken and stored
at  801C. Samples were analysed for sodium selenate (parent) and
its various metabolites using ion chromatography dynamic
reaction cell inductively coupled plasma mass spectrometry (Kuo
and Jiang, 2008).
Pharmacokinetic analysis
Pharmacokinetic results were processed according to standard
non-compartmental analytical procedures (Win Non Lin v5.2,
Pharsight Corporation, Mountain View, CA, USA). The actual
times of sample collections were used in the calculations.
Parameters measured included Cmax, Cmin, Tmax and AUClast.
AUC was determined by the linear trapezoidal rule, where AUClast
was the AUC from time zero until the last concentration point. The
elimination rate constant, Kel (h
 1) was determined by linear
regression of a minimum of three points. Half-life (t1/2) was
determined according to t1/2¼0.693Kel
–1.
Statistical evaluations
All data presented are descriptive and no formal statistical
evaluation was performed.
RESULTS
Patient characteristics
Between June 2006 and November 2008, a total of 19 patients were
enrolled in the study and their clinical characteristics are
summarised in Table 1. The median age was 72 years and the
mean PSA was 22mgl
–1, with an average PSA doubling time of 2.2
months (1.1–8.9). In all, 7 of 19 patients (36.9%) had previously
received treatment to the primary tumour, three with radical
surgery and four with external beam radiotherapy. The remaining
12 patients had androgen deprivation as their only prostate cancer
treatment. In all, 10 of 19 patients (52.6%) had metastatic bone
disease at the time of enrolment.
Safety results
Of the 19 patients enrolled into the study, 12 patients (63%)
completed the 12-week treatment period (Table 2). In all, 6 of the
12 patients who completed the 12-week study period continued to
receive study drug beyond this time for a total treatment period
ranging from 23–28 weeks. Seven patients withdrew from the
study drug before completion of the main treatment phase due to
disease progression (four patients), unacceptable toxicity (two
patients, one with grade 3 fatigue and one with concomitant grade
3 diarrhoea and muscle cramps) or the occurrence of an adverse
event (one patient with acute renal impairment)
Table 3 documents the toxicities observed during the study
thought to be at least possibly related to sodium selenate. The
majority (76%) were classified as grade 1, whereas 20% were
classified as grade 2. Five grade 3 toxicities (fatigue, nail disorders,
muscle spasms and diarrhoea) were reported by three patients in
the 90-mg (30mg t.d.s.) cohort. All of these events resolved,
although two of the three patients required that study drug be
Table 1 Patient characteristics
n 19
Mean age (range), years 72 (58–78)
Caucasian, n (%) 19 (100)
Mean PSA (range), mgl
–1 22 (7.5–245.1)
Mean PSAdt (range), months 2.18 (1.05–8.94)
Bone metastases (%) 10 (52.6)
Mean haemoglobin (range), gl
–1 137.6 (109–166)
Mean alkaline phosphatase (range), Ul
–1 126.6 (59–491)
WHO performance status
01 5
14
Previous therapy (%)
Radical prostatectomy 3 (15.8)
EBRT 4 (21.1)
Median Gleason score (range) 8 (6-10)
Abbreviations: EBRT¼External beam radiotherapy; PSA¼prostate-specific antigen;
PSAdt¼PSA doubling time; WHO¼World Health Organisation.
Table 2 Dose escalation and treatment completion
Dose N
Completed
12-week
treatment Reason for withdrawal
5mg per day 1 Yes
10mg per day 1 Yes
15mg per day 1 Yes
30mg per day 1 Yes
30mg (10mg t.d.s.) 3 No Disease progression
Yes
Yes
45mg (15mg t.d.s.) 2 Yes
Yes
60mg (20mg t.d.s.) 6 No Disease progression
No Disease progression
No Disease progression
Yes
Yes
No Adverse event
(renal impairment)
90mg (30mg t.d.s.) 4 No DLT (grade 3 fatigue)
Yes
Yes
No DLT (grade 3 diarrhoea and
muscle spasms)
Abbreviation: DLT¼dose-limiting toxicity.
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spermanently discontinued. No grade 4 events were reported and
there were no deaths on study.
Two events considered to be DLTs (grade 3 fatigue, and
concomitant grade 3 diarrhoea and intermittent muscle cramps)
were reported by two patients in the 90-mg (30mg t.d.s.) cohort.
Thus, 60mg (20mg t.d.s.) was determined to be the MTD. The
DRTs were seen in the 60-mg (20mg t.d.s.) and 90-mg (30mg
t.d.s.) cohorts. Fatigue was the most commonly reported DRT.
A total of five serious adverse events were reported by five
patients, only one of which was considered to have a potential
causal relationship to sodium selenate. This was a patient in the
90-mg (30mg t.d.s.) cohort who presented with an elevated
creatinine level of 260mmoll
–1 (as compared with 90mmoll
–1at
screening) when scheduled biochemistry assessments were per-
formed at the end of the first cycle of treatment. At this visit, the
patient was also noted to have decreased bicarbonate levels
(19mmoll
–1 compared with 30mmoll
–1at screening), associated
with diarrhoea and dehydration. The study drug was stopped
immediately and the patient was admitted for investigation of
acute renal impairment. Examination of the patient’s clinical
records revealed the patient had a history of proteinuria, macro-
haematuria and underlying kidney disease before commencing
sodium selenate. Despite investigation, no cause for the acute
deterioration in renal function could be determined, and a
contribution of sodium selenate to the existing underlying renal
disease cannot be ruled out. Creatinine levels were further elevated
to 290mmoll
–1 when re-tested 12 weeks after the last study dose,
although bicarbonate levels had normalised. The four serious
adverse events considered not to be associated with the study drug
were episodes of pelvic pain, bowel obstruction, renal colic and
lower respiratory tract infection.
Apart from the patient described above, there were no clinically
significant laboratory results considered to be potentially related to the
study drug, and no patients were found to have vital sign assessments
or ECG results that were abnormal and clinically significant.
Pharmacokinetic and metabolic profile
The PK parameters are detailed in Table 4. Sodium selenate
exhibited linear pharmacokinetics, in terms of AUC vs dose, across
the dose ranges assessed in this study, with the caveat of small
Table 3 Toxicity experienced by X2 patients thought to be at least
possibly related to the study drug
SOC
Preferred
term
Grade 1/2
(%)
Grade 3
(%)
Gastrointestinal disorders Constipation 4 (21) 0 (0)
Diarrhoea 4 (21) 1 (5)
Nausea 5 (26) 0 (0)
Retching 2 (10) 0 (0)
Vomiting 4 (21) 0 (0)
General disorders Fatigue 8 (42) 1 (5)
Metabolism and nutrition Decreased
appetite
5 (26) 0 (0)
Musculoskeletal and connective tissue
disorders
Arthralgia 2 (10) 0 (0)
Muscle spasms 8 (42) 1 (5)
Myalgia 3 (16) 0 (0)
Nervous system Dizziness 4 (21) 0 (0)
Headache 3 (16) 0 (0)
Hypoaesthesia 2 (10) 0 (0)
Lethargy 5 (26) 0 (0)
Skin Alopecia 8 (42) 0 (0)
Nail disorders 5 (26) 1 (5)
Pain of skin 2 (10) 0 (0)
Table 4 Pharmacokinetic parameters for selenate for all patient cohorts
AUC0–24h
(nghml
–1)
AUC0–168h
(nghml
–1)
AUC0–336h
(nghml
–1)
AUClast
(nghml
–1) T1/2 (h)
Tmax (0 last)
(h)
Cmax (0 last)
(ngml
–1)
Cmin (0 last)
(ngml
–1)
Single daily dose (mg)
5 — — — 126.9 1.23 1 56 2.78
10 — — — 8311.9 1.61 1 112 30.6
15 — — — 440.8 1.38 0.7 154 40.3
30 — — — 666.4 2.9 2.2 166 65.3
Mullti-dose
30mg (10mg t.d.s.)
n 333 3 3 33 3
Mean 502.39 1290.5 2049.3 2763.37 1.72 1.43 98.13 2.86
s.d. 161.92 293 426.7 972.46 0.25 0.6 56.36 0.91
CV % 32.23 22.7 20.8 35.19 14.8 42.05 57.43 31.85
45mg (15mg t.d.s.)
n 222 2 2 22 2
Mean 549.1 2232.2 8437.1 15130.3 2.14 169.6 107.5 6.63
s.d. 17.5 92.8 6884.9 13931.5 1.34 237.1 19.2 1.99
CV % 3.2 4.2 81.6 92.1 62.6 139.8 17.8 29.99
60mg (20mg t.d.s.)
n 666 6 6 66 6
Mean 1232.9 7201.1 11678.7 14354.7 3.09 2.6 165 11.23
s.d. 684 5892.2 9275.6 9632 1.04 1.2 72.3 5.57
CV % 55.5 81.8 79.4 67.1 32.5 46.1 43.9 49.61
90mg (30mg t.d.s.)
n 443 3 4 44 4
Mean 1313.6 9783.1 15921.1 21521.4 2.26 13.4 218.8 18.63
s.d. 163.7 1862.6 3671.2 6843.7 0.58 23.5 90.7 8.73
CV % 12.5 19 23.1 31.8 25.7 174.7 41.5 46.87
Abbreviation: CV¼coefficient of variance.
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scohort size. The selenate t1/2 ranged from 1.2 to 2.9h in the
5–30mg single-dose cohorts, respectively. The short half-life
necessitated a three times a day daily dosing regimen to maintain
adequate blood levels of sodium selenate. Peak selenate plasma
concentrations were achieved within 1–4h across all dose levels.
At the recommended phase II dose, that is, 20mg t.d.s., the mean
tmax was 2.5h and the mean t1/2 was 2.9h.
The major selenium metabolite identified in plasma was selenite.
Its plasma concentrations showed signs of accumulation, with tmax
ranging from a mean of 90h for the 10mg t.d.s. cohort to 294h for
the 30mg t.d.s. cohort (data not shown). Plasma selenite levels
reached steady-state levels by 3 weeks. The ratio of selenite AUC504
vs selenate AUC504 ranged from 1.3  at 10mg t.d.s. to 7  at the
30mg t.d.s. dose level. Seleno-methionine, seleno-cyanate and
methyl selenium species were other significantly minor meta-
bolites identified in plasma. For the t.d.s. dosing cohorts, 16–37%
of total daily dose of selenium was recovered in the 24-h urine.
Selenate was the major selenium species identified in the 24-h
urine accounting for 10–24% (based on the mean for each t.d.s.
dosing cohort) of total daily selenium administered. Seleno-
methionine and miscellaneous methyl selenium species were also
major selenium compounds identified in 24-h urine; however,
levels varied significantly across the patients in the t.d.s. dosing
cohorts. Selenite was barely detectable in the urine, being o0.3%
of total daily dose.
Efficacy
Although the study was not designed to determine clinical efficacy,
PSA was monitored throughout the trial as a surrogate marker of
tumour response. The percentage change in PSA from baseline for
each individual patient is shown in Figure 1. One patient from the
60-mg (20mg t.d.s., patient 14) cohort experienced a significant
PSA decline (maximal change in PSA from baseline  57.4%) that
was maintained for 11 weeks and two patients (both from the 30-
mg (10mg t.d.s.) cohort) had disease stabilisation lasting 28 and 41
weeks, respectively. For those patients who completed the initial
12-week evaluation (n¼12), median time to progression was 14.2
weeks (13.1–41.1)
Mean doubling time increased from 2.2 months (1.1–9.0) before
trial to 3.9 months (1.1 to  2.0) during the main treatment phase
(Figure 2).
DISCUSSION
The management of metastatic prostate cancer has changed
significantly in the past decade. Cytotoxic chemotherapy with
docetaxel is a standard of care in castrate-resistant disease and new
therapies, including hormone agents such as abiraterone, show
promising activity. However, no current therapy is curative and
novel therapies are still needed. Most recently, many clinical trials
have focussed on anti-angiogenic agents targeting critical kinases.
We have previously identified that the specific selenium-
containing compound, sodium selenate, significantly boosts the
activity of the protein phosphatase PP2A, inhibits VEGF-induced
growth and survival signalling in endothelial cells, and impedes
tumour neovascularisation.
This ‘first-in-human’ study examined the use of sodium selenate
in men with CRPC before they received cytotoxic chemotherapy.
Sodium selenate was well tolerated at doses up to 45mg per day
t.d.s. and the MTD was attained at a dose of 60mg per day t.d.s.
DLT was fatigue and diarrhoea, while other frequently reported
adverse events included, nail disorders, muscle spasms, alopecia
and nausea. Some of the side effects observed at the higher doses,
in particular the fatigue, diarrhoea, alopecia and vomiting are
perhaps attributable to the accumulation of the inorganic
metabolite selenite, a selenium compound with marked cytotoxic
properties and a very different pharmacokinetic profile compared
with selenate, as confirmed in this study (Lu et al, 2009).
The study was not designed to evaluate the efficacy of sodium
selenate. However, one PSA response was observed and two other
patients appeared to have some stabilisation of disease. This
modest activity is consistent with single-agent studies of other
anti-angiogenic agents, including bevacizumab, sorafenib and
sunitinib (Reese et al, 2001; Chi et al, 2008; Dror Michaelson
et al, 2009).
On the bases of these observations, it would be reasonable to
question the importance of angiogenesis to the development of
prostate cancer. However, the continual development of a new
vascular network is required to support the growth and increase in
size of all solid tumours. The density of the vascular network that
is established in any given tumour might reasonably be expected to
reflect the growth, progression and metastatic potential of that
tumour (Folkman, 1971), and indeed, tumour vascularity as
measured by MVD has been shown to be a prognostic factor in
a range of solid malignancies including that of prostate cancer
(Weidner et al, 1991; Weidner, 1993; Weidner and Folkman, 1996;
Strohmeyer et al, 2000).
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Figure 1 Waterfall plot of percentage change in prostate-specific antigen
(PSA) from baseline to the end of the 12-week evaluation period
(or withdrawal if earlier) for each patient.
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sMost of the evidence linking angiogenesis with prostate cancer
progression has come from studies evaluating total MVD in
prostate tumour samples, which almost invariably demonstrate a
positive correlation with other histological features of tumour
aggression and/or adverse clinical outcomes. However, as pre-
viously proposed, MVD may be poor surrogate of a tumour
angiogenic potential, rather more accurately reflects tissue
metabolic activity (Hlatky et al, 2002). Recent findings in renal
cell carcinoma suggest that the relative degree of vessel
differentiation within tumours correlates more closely with
angiogenic activity than total MVD, with high densities of
undifferentiated vessels significantly associated with higher
tumour grades and shorter patient survival, in contrast to high
densities of differentiated, vessel which correlated significantly
with lower tumour grade and longer survival (Yao et al, 2007).
Similar findings have been reported in prostate cancer samples,
with significantly higher levels of proliferating immature tumour
vessels identified in castration-resistant or metastatic tissue
compared to organ confined cancers or benign tissue (Gravdal
et al, 2009). More importantly, higher levels of immature vessels in
radical prostatectomy specimens were a strong and independent
predictor of biochemical failure, clinical recurrence or the
development of bony metastases in multivariate analyses, con-
firming the clinical importance of angiogenesis in prostate cancer
progression.
The expectation that single-agent anti-angiogenic therapy will
result in the same type of clinical responses that are observed with
traditional cytotoxic agents is based on the assumption that either
the tumour itself, or the vascular network that supports it, is
critically dependent on the signalling pathway inhibited. However,
with the notable exception of clear cell renal carcinoma (CCRCC),
significant or sustained responses are rarely observed with single-
agent therapy. This clinical difference may simply reflect the
strength of angiogenic drive within different tumour types, as renal
cancers, together with glioblastomas, have the highest rates of
endothelial cell proliferation and levels of immature blood vessels
of tumour types studied, certainly significantly higher than
prostate cancer, and thus may be more intrinsically sensitive to
angiogenic inhibition (Eberhard et al, 2000). In addition, given the
high frequency of VHL mutations in CCRCC, angiogenesis may be
much more dependent on VEGF signalling than in prostate cancer,
in which multiple redundant pathways have been implicated
(Gravdal et al, 2006; Kim et al, 2006; Bergers and Hanahan, 2008;
Yang et al, 2008). In future studies, the identification of prostate
cancer patients most likely to respond to anti-angiogenic therapies,
either by measuring levels of immature vessels in pretreatment
biopsies, or by global markers of vessel turnover such as with
circulating endothelial cells or their progenitors, may be important
(Georgiou et al, 2008).
Despite their lack of single-agent activity, anti-angiogenic agents
have shown favourable effects in boosting the efficacy of standard
chemotherapy regimens in different tumour types (Ellis and
Hicklin, 2008). Interestingly, this effect may be independent of a
direct effect on new blood vessel formation, but more reliant on a
relative normalisation of the vascular network and blood flow
within tumours, improving delivery of chemotherapy. Disappoint-
ingly however, the recently completed but yet to be reported
CALBG phase III study of docetaxel±bevacizumab (CALGB
90401) in men with CRPC failed to demonstrate an improvement
in survival compared with chemotherapy alone (http://www.
roche.com/media/media_releases/med-cor-2010-03-12.htm). As only
the VEGF signalling pathway was targeted, it is possible that
combining anti-angiogenic agents with different mechanisms of
action can overcome the inherent redundancy in angiogenic
signalling in prostate cancer, and improve clinical response rates.
This is supported by recently published phase II data exploring the
combination of docetaxel, bevacizumab, thalidomide and pre-
dnisone, with 90% of patients experiencing a PSA decline of X50%
(Ning et al, 2010).
Further exploration of sodium selenate as a single-agent in
CRPC is not warranted; however, its combination with conven-
tional cytotoxics in particular docetaxel, as well as with other
anti-angiogenics with different modes of action is worthy of
further exploration.
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